Top Analyst Upgrades and Downgrades: Arena Pharma, Autodesk, Coca-Cola, GE, Marvell, Monster Beverages, Nabors, Procter & Gamble and More
The futures traded slightly higher Thursday morning as the markets digested yesterday’s upside move. Positive talk on trade and some more benign inflation data were seen as the key reasons for the rally. Unfortunately, investors have to keep in mind that there has been less upside from buying immediately after the big market sell-offs than in prior years. Now investors have to consider how they want their investments and assets positioned for 2019.
24/7 Wall St. reviews dozens of analyst research reports each day of the week. Our goal is to find new ideas for investors and traders alike. Some of these analyst reports cover stocks to buy, while others cover stocks to sell or to avoid.
Additional commentary has been added on most of the daily analyst reports, along with trading history. The consensus analyst price targets and other valuation metrics are from the Thomson Reuters sell-side research service.
These are the top analyst upgrades, downgrades and initiations seen on Thursday, December 13, 2018.
Arena Pharmaceutical Inc. (NASDAQ: ARNA) was started with Buy rating at Berenberg with a $55 price target, and that compares with a Wall Street consensus target of $62.78. The shares closed Wednesday at $42.67.
Autodesk Inc. (NASDAQ: ADSK) was downgraded to Neutral from Overweight at JPMorgan. The shares have traded between $101.55 and $159.54. The consensus price target is $166.36. The stock closed Wednesday at $137.79.
General Electric Co. (NYSE: GE) was raised to Neutral from Underweight at JPMorgan with a $6 price target. The venerable industrial has been pounded this year, and the change is a boost for the company as the analyst has been a long-time bear on the shares. The stock has traded between $6.66 and $19.39 over the past year. The consensus price target is $12.83. The stock closed Wednesday at $6.71, but shares are up almost 12% premarket on the upgrade.
Intuit Inc. (NASDAQ: INTU) was downgraded to Underweight from Neutral at JPMorgan. The 52-week trading range is $150.43 to $231.84, and the consensus price target is leveled at $226.33. The stock closed Wednesday at $209.18, but shares are down 2% premarket.
Marvell Ltd. (NASDAQ: MRVL) was raised to Buy from Neutral at Citigroup. The 52-week trading range for the stock is $14.69 to $25.18, and the consensus price target is $23.72. The stock closed Wednesday at $145.35, but shares are up almost 3.5% premarket.
Monster Beverage Corp. (NASDAQ: MNST) was started with a Sell rating at UBS, which has a $48 price target. That figure compares with a consensus price target of $62.71. The shares closed trading on Wednesday at $57.44.
Nabors Industries Ltd. (NYSE: NBR) was downgraded to Market Perform from Outperform at Raymond James. The 52-week trading range is $2.75 to $8.87. The consensus price target is still a massive $8.24. Shares closed Wednesday at $2.85 and were down slightly in the premarket.
Nektar Therapeutics Inc. (NASDAQ: NKTR) was started with a Buy rating at Goldman Sachs, which has a price target of $62. That is in comparison to a massive consensus target of $81. The stock closed up smartly on Wednesday at $36.97, and shares were up over 4% in premarket action.